Skip to content

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05313828
Enrollment
40
Registered
2022-04-06
Start date
2022-03-18
Completion date
2022-07-20
Last updated
2022-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Ulcer

Brief summary

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections\]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK. In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

Interventions

DRUGAcyclovir

acyclovir 4 times /day

DRUGTobramycin

tobramycin 4 times /day

Fluorometholone 4 times/ day

DRUGSodium Hyaluronate

Sodium Hyaluronate 4 times/day

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

patients with epithelial viral ulcers \-

Exclusion criteria

* patients with stromal keratitis patients with corneal opacity

Design outcomes

Primary

MeasureTime frameDescription
healing of the epithelium10 days follow upthe epithelial healing assessed with flourescin stain and measured by slit lamp scale in millimetres and compared with pre treatment epithelial defect

Countries

Egypt

Contacts

Primary ContactHany Mahmoud
drhanymahmoud@gmail.com00201024368111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026